Evidence map›Paper›PMID 41531498›Full record

ArticleMaterials today. Bio2026

Modulation of endothelial-to-mesenchymal transition via NRP-1 targeting with melittin attenuates pulmonary fibrosis.

Ming Hu, Yingying Wan, Jiakang Chen, Chengwei Zhang, Shuze Li, Bingbing Shan, Ling Wu, Xiang Yu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ming HuState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, China.
Yingying WanHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, China.
Jiakang ChenState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, China.
Chengwei ZhangHubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, China.
Shuze LiState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, China.
Bingbing ShanState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, China.
Ling WuSanya Yazhou Bay Science and Technology City Hospital, Sanya, China.
Xiang YuState Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transforming growth factor-β (TGF-β) signaling pathway is a central driver in the pathogenesis of pulmonary fibrosis (PF), and strategies targeting this pathway demonstrate therapeutic potential. However, the ubiquitous blockade of TGF-β signaling is associated with detrimental effects due to its pleiotropic involvement in physiological processes. Here, we demonstrate that blocking neuropilin-1 (NRP-1), a high-affinity TGF-β co-receptor, with host defense peptide melittin (MLT) attenuates PF progression. Molecular docking and surface plasmon resonance (SPR) demonstrated direct binding between MLT and NRP-1.

Indexed as

EndMTMelittinNRP-1Peptide-lipid nanoparticles

Identifiers

PMID41531498
PMCPMC12794516

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.